Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvima and Keytruda in non-clear cell renal cell carcinoma
NCT04267120Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2020
- Primary completion
- May 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and pembrolizumab in non-clear cell renal cell carcinoma (nccRCC), sponsored by Washington University School of Medicine. Primary endpoint: Overall Response Rate. Started Jul 2020; status: terminated.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT04267120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267120.